Spots Global Cancer Trial Database for lisocabtagene maraleucel

Every month we try and update this database with for lisocabtagene maraleucel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy	NCT06357754	Non-Hodgkin Lym... Chronic Lymphoc... Multiple Myelom...	Idecabtagene vi... Lisocabtagene m...	-	Bristol-Myers Squibb
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma	NCT06313996	Relapsed or Ref...	Cyclophosphamid... Doxorubicin Vincristine Rituximab Prednisone Bendamustine Lenalidomide Fludarabine Liso-cel	18 Years -	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	NCT05633615	Diffuse Large B... Grade 3b Follic... Primary Mediast... Recurrent Diffu... Refractory Diff... Transformed Fol... Transformed Mar...	Axicabtagene Ci... Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Lisocabtagene M... Mosunetuzumab Patient Observa... Polatuzumab Ved... Positron Emissi... Tisagenlecleuce...	18 Years -	SWOG Cancer Research Network
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome	NCT05873712	Recurrent Trans... Refractory Tran... Transformed Chr... Recurrent Trans... Recurrent Trans... Refractory Tran... Refractory Tran... Refractory Tran...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lisocabtagene M... Lymph Node Biop... Positron Emissi... Zanubrutinib	18 Years -	Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma	NCT06313996	Relapsed or Ref...	Cyclophosphamid... Doxorubicin Vincristine Rituximab Prednisone Bendamustine Lenalidomide Fludarabine Liso-cel	18 Years -	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy	NCT05075603	Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran...	Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M...	18 Years -	NeoImmuneTech
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy	NCT05075603	Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran...	Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M...	18 Years -	NeoImmuneTech
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)	NCT03744676	Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D...	lisocabtagene m...	18 Years -	Juno Therapeutics, a Subsidiary of Celgene
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation	NCT05672173	Recurrent Trans... Refractory Tran... Richter Syndrom...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Ibrutinib Lisocabtagene M... Nivolumab Pheresis Positron Emissi...	18 Years -	City of Hope Medical Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: